Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Remote Intervention Versus Routine Monitoring in COPD Patients With Chronic Hypercapnia Receiving Home Non-invasive Respiratory Support

3 augusti 2026 uppdaterad av: Huiqing Ge, Sir Run Run Shaw Hospital

A Randomized Controlled Trial of Remote Intervention Versus Routine Monitoring in COPD Patients With Chronic Hypercapnia Receiving Home Non-invasive Respiratory Support

This study is a randomized controlled trial designed to compare the effectiveness of active remote intervention versus passive monitoring alone in patients with Chronic Obstructive Pulmonary Disease (COPD) and chronic hypercapnic respiratory failure who are receiving home non-invasive respiratory support. The primary goal is to evaluate the impact on health-related quality of life and the frequency of acute exacerbations over a 12-month period.

Studieöversikt

Detaljerad beskrivning

Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality worldwide. A subset of patients with severe COPD develops chronic hypercapnic respiratory failure, often requiring long-term home non-invasive ventilation (NIV). While NIV can improve gas exchange, optimal management strategies, particularly post-hospitalization, are still being investigated.

This study aims to determine if a proactive, remote management strategy can improve patient outcomes compared to standard care with passive monitoring.

Experimental Group (Remote Intervention): Participants will receive home NIV with remote monitoring. A respiratory therapist will actively review ventilation data, assess oxygenation, and perform remote parameter adjustments and individualized optimization based on pre-set conditions and risk predictions.

Control Group (Monitoring Control): Participants will receive home NIV with remote monitoring. However, the study team will not perform active interventions based on the monitoring data. Patients will continue with their usual care and follow-up with their primary physician. The study team will only make contact in case of a severe safety risk.

The study will enroll 236 participants who will be randomized 1:1 to one of the two groups. The primary outcomes are the change in health-related quality of life and the number of COPD exacerbations over 12 months.

Studietyp

Interventionell

Inskrivning (Beräknad)

236

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Huiqing Ge, MD, PhD
  • Telefonnummer: +86 13588706787
  • E-post: gehq@zju.edu.cn

Studieorter

    • Henan
      • Zhengzhou, Henan, Kina
        • Henan Provincial People's Hospital
        • Kontakt:
    • Hunan
      • Changsha, Hunan, Kina, 410006
        • The Second Xiangya Hospital of Central South University
        • Kontakt:
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310016
        • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
        • Kontakt:
      • Wenling, Zhejiang, Kina, 317523
        • Taizhou Hospital of Integrated Traditional Chinese and Western Medicine
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Meets the diagnostic criteria for Chronic Obstructive Pulmonary Disease (COPD) with confirmed persistent airflow limitation by spirometry.
  • Hospitalized due to an acute exacerbation of COPD.
  • Stable daytime arterial blood gas analysis showing PaCO₂ ≥ 50 mmHg, with hypoxemia.
  • Already receiving or planned to receive long-term home non-invasive respiratory support.
  • Capable of using a smartphone or tablet for video communication and has internet access.
  • Willing to participate and provides written informed consent.

Exclusion Criteria:

  • Concurrent severe pulmonary diseases (e.g., active tuberculosis, diffuse pulmonary fibrosis, advanced lung cancer).
  • Chronic respiratory failure primarily caused by non-COPD conditions (e.g., neuromuscular disease, chest wall deformity, or severe obesity hypoventilation syndrome).
  • Severe cognitive impairment or psychiatric illness that would prevent cooperation with remote management.
  • Other severe systemic diseases with an expected survival of less than 1 year (e.g., advanced malignancy).
  • Pregnant or lactating women.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Remote Intervention Group
Participants will receive home non-invasive respiratory support combined with active remote management.
Participants will receive home non-invasive respiratory support combined with active remote management. This includes regular analysis of ventilation data, assessment of oxygenation status, risk prediction, and remote parameter adjustment by a respiratory therapist.
Participants will receive home non-invasive respiratory support with remote monitoring only. No active intervention will be performed by the study team based on the data. Patients will continue with standard care from their primary physician.
Aktiv komparator: Monitoring Control Group
Participants will receive home non-invasive respiratory support with remote monitoring only.
Participants will receive home non-invasive respiratory support with remote monitoring only. No active intervention will be performed by the study team based on the data. Patients will continue with standard care from their primary physician.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in Health-Related Quality of Life
Tidsram: Baseline to 12 months
Measured by the change from baseline in the total score of the St. George's Respiratory Questionnaire (SGRQ) questionnaire at 12 months.
Baseline to 12 months
Number of COPD Exacerbations
Tidsram: 12 months
The number of acute exacerbations requiring antibiotics and/or systemic corticosteroids within 12 months.
12 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in PaCO₂
Tidsram: Baseline, 1, 3, 6, 12 months
The change from baseline in arterial partial pressure of carbon dioxide (PaCO₂) at 1, 3, 6, and 12 months.
Baseline, 1, 3, 6, 12 months
Changes in PaO₂
Tidsram: Baseline, 1, 3, 6, 12 months
The change from baseline in arterial partial pressure of oxygen (PaO₂) at 1, 3, 6, and 12 months.
Baseline, 1, 3, 6, 12 months
Change in Dyspnea Severity (mMRC Score)
Tidsram: Baseline, 1, 3, 6, 12 months
The change from baseline in the modified Medical Research Council (mMRC) dyspnea scale score to each follow up. The scale ranges from 0 to 4, with higher scores indicating more severe dyspnea.
Baseline, 1, 3, 6, 12 months
Change in CAT Score
Tidsram: Baseline, 1, 3, 6, and 12 months
The change from baseline in the total score of the COPD Assessment Test (CAT) at 1, 3, 6, and 12 months.
Baseline, 1, 3, 6, and 12 months
Change in SRI Score
Tidsram: Time Frame: Baseline, 1, 3, 6, and 12 months
The change from baseline in the total score of the Severe Respiratory Insufficiency (SRI) questionnaire at 1, 3, 6, and 12 months.
Time Frame: Baseline, 1, 3, 6, and 12 months
Average daily usage of Non-invasive Ventilation
Tidsram: Baseline, 1, 3, 6, and 12 months
Average daily usage of the non-invasive ventilation device (hours per day) recorded at 1, 3, 6, and 12 months.
Baseline, 1, 3, 6, and 12 months
Adherence-Percentage of days with usage greater than 4 hours
Tidsram: Baseline, 1, 3, 6, and 12 months
Percentage of days with usage greater than 4 hours, recorded at 1, 3, 6, and 12 months.
Baseline, 1, 3, 6, and 12 months
Adverse Events
Tidsram: Baseline, 1, 3, 6, and 12 months
The number and type of adverse events (AEs) and serious adverse events (SAEs) reported throughout the 12-month study duration.
Baseline, 1, 3, 6, and 12 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 augusti 2027

Primärt slutförande (Beräknad)

31 december 2027

Avslutad studie (Beräknad)

31 december 2028

Studieregistreringsdatum

Först inskickad

30 juli 2026

Först inskickad som uppfyllde QC-kriterierna

3 augusti 2026

Första postat (Faktisk)

6 augusti 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

6 augusti 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 augusti 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera